Cargando…

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

PURPOSE: PIK3CA gene encoding a catalytic subunit of the phosphatidylinositol-3-kinase (PI3K) is mutated and/or amplified in various neoplasia, including lung cancer. Here we investigated PIK3CA gene alterations, the expression of core components of PI3K pathway, and evaluated their clinical importa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Lei, Hu, Haichuan, Pan, Yunjian, Wang, Rui, Li, Yuan, Shen, Lei, Yu, Yongfu, Li, Hang, Cai, Deng, Sun, Yihua, Chen, Haiquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922761/ https://www.ncbi.nlm.nih.gov/pubmed/24533074 http://dx.doi.org/10.1371/journal.pone.0088291

Ejemplares similares

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
por: Li, S, et al.
Publicado: (2014)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients
por: Sharma, Aarti, et al.
Publicado: (2017)

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer
por: Li, Shuo, et al.
Publicado: (2021)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials
por: Zhang, Yiliang, et al.
Publicado: (2013)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations
por: Ramteke, Manoj P., et al.
Publicado: (2016)

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
por: Krakstad, Camilla, et al.
Publicado: (2012)

EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features
por: Jia, Xiaoli, et al.
Publicado: (2015)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma
por: Smits, Alexander J. J., et al.
Publicado: (2012)

KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
por: Siddiqui, Ahmad D., et al.
Publicado: (2009)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
por: Planck, Maria, et al.
Publicado: (2013)

Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers
por: TAKAMOCHI, KAZUYA, et al.
Publicado: (2013)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
por: Li, Hang, et al.
Publicado: (2014)

Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing
por: Cai, Xin, et al.
Publicado: (2014)

Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer
por: Wang, Chengfeng, et al.
Publicado: (2022)

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
por: Hu, Jing, et al.
Publicado: (2016)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
por: Heriyanto, Didik Setyo, et al.
Publicado: (2022)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
por: Prencipe, Berardino, et al.
Publicado: (2023)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations
por: Zheng, Difan, et al.
Publicado: (2016)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_90ktg1pk0ru4k3t9ntmno1d6lm